Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmisartan + amlodipine + indapamide is a fixed-dose, single-pill combination of three antihypertensive agents developed for the treatment of hypertension. The combination includes: - Telmisartan, an angiotensin II receptor blocker (ARB) that inhibits the action of angiotensin II on its receptor, leading to vasodilation and reduced blood pressure. - Amlodipine, a calcium channel blocker (CCB) that relaxes vascular smooth muscle by inhibiting calcium influx into cells. - Indapamide, a thiazide-like diuretic that promotes sodium and water excretion to lower blood volume and pressure. This triple combination is designed to provide rapid and effective blood pressure control with improved tolerability compared to higher doses of individual agents. It has been evaluated in phase III clinical trials for efficacy and safety in adults with hypertension. The product aims to improve patient adherence by simplifying therapy into one pill[1][2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + amlodipine + indapamide.